CTI BioPharma Corp. (CTIC) financial statements (2020 and earlier)

Company profile

Business Address 3101 WESTERN AVENUE
SEATTLE, WA 98121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:476727441287172
Cash and cash equivalents353627441287172
Short-term investments1231     
Other undisclosed cash, cash equivalents, and short-term investments(0)(0)     
Restricted cash and investments  16    
Receivables0 00020
Inventory, net of allowances, customer advances and progress billings  12345
Inventory  12345
Other undisclosed current assets315310434
Total current assets:508247561358181
Noncurrent Assets
Property, plant and equipment1223455
Other noncurrent assets8665678
Total noncurrent assets:978891213
TOTAL ASSETS:599055641449294
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14171632333218
Accounts payable34371165
Accrued liabilities1113142522209
Employee-related liabilities     63
Taxes payable     0 
Debt105083793
Derivative instruments and hedges, liabilities      1
Deferred revenue and credits10111
Other liabilities3111200
Other undisclosed current liabilities     (6)(3)
Total current liabilities:28231941723620
Noncurrent Liabilities
Long-term debt and lease obligation 9141119810
Long-term debt, excluding current maturities 9141119810
Liabilities, other than long-term debt45645127
Deferred revenue and credits01162
Other liabilities4554466
Other undisclosed noncurrent liabilities     (4) 
Total noncurrent liabilities:4142015251617
Total liabilities:32373956975238
Temporary equity, carrying amount     113
Stockholders' equity
Stockholders' equity attributable to parent, including:32592213524245
Preferred stock  1    
Common stock00     
Additional paid in capital2,2982,294     
Accumulated other comprehensive loss(11)(11)(6)(7)(7)(6)(8)
Accumulated deficit(2,255)(2,225)(2,195)(2,150)(2,098)(1,976)(1,880)
Other undisclosed stockholders' equity attributable to parent  2,2222,1702,1572,0241,933
Stockholders' equity attributable to noncontrolling interest(6)(6)(6)(6)(5)(3)(2)
Total stockholders' equity:2653168473843
TOTAL LIABILITIES AND EQUITY:599055641449294

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues18262557166035
Revenue, net2557167735
Cost of revenue(4)(5)(0) (2)(1) 
Cost of goods and services sold (1)(0) (2)(1) 
Gross profit:14222557145935
Operating expenses(45)(55)(64)(110)(131)(147)(95)
Other operating income, net   5   
Other undisclosed operating income (loss)(0)  (1) 119
Operating loss:(31)(33)(40)(49)(117)(86)(42)
Nonoperating income (expense)04(1)(4)(4)(8)(2)
Investment income, nonoperating11     
Foreign currency transaction gain (loss), before tax0(0)1(0)(1)(4)0
Other nonoperating income (expense) 4(0)(0)(1)(1) 
Interest and debt expense(1)(1)(0)(3)(1)(2)(1)
Loss before gain (loss) on sale of properties:(32)(31)(41)(56)(122)(96)(45)
Other undisclosed net income1103121
Net loss:(31)(29)(41)(53)(121)(94)(44)
Net income attributable to noncontrolling interest0001111
Net loss attributable to parent:(31)(29)(41)(52)(119)(93)(43)
Preferred stock dividends and other adjustments (0)(4) (3)(3)(7)
Net loss available to common stockholders, diluted:(31)(29)(45)(52)(123)(96)(50)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(31)(29)(41)(53)(121)(94)(44)
Other comprehensive income (loss)(1)(4)00(0)2(0)
Comprehensive loss:(32)(34)(40)(53)(121)(92)(44)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest000111(1)
Other undisclosed comprehensive income, net of tax, attributable to parent      2
Comprehensive loss, net of tax, attributable to parent:(32)(34)(40)(52)(120)(91)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: